These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37248486)

  • 1. Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis.
    Liu W; Bai D; Kou L
    BMC Ophthalmol; 2023 May; 23(1):240. PubMed ID: 37248486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy, safety, and cumulative retention rate of antitumor necrosis factor-alpha treatment for patients with Behcet's uveitis: A systematic review and meta-analysis.
    Guan X; Zhao Z; Xin M; Xia G; Yang Q; Fu M
    Int J Rheum Dis; 2024 Feb; 27(2):e15096. PubMed ID: 38402428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.
    Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG
    Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.
    Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS
    J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.
    Maalouf G; Andrillon A; Leclercq M; Sève P; Bielefeld P; Gueudry J; Sené T; Titah C; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; Thibault T; Chamieh CE; Cacoub P; Kodjikian L; Biard L; Bodaghi B; Saadoun D
    Am J Ophthalmol; 2022 Jun; 238():173-180. PubMed ID: 35172172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review.
    Ming S; Xie K; He H; Li Y; Lei B
    Drug Des Devel Ther; 2018; 12():2005-2016. PubMed ID: 30013320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study.
    Sharma SM; Damato E; Hinchcliffe AE; Andrews CD; Myint K; Lee R; Dick AD
    Br J Ophthalmol; 2021 Sep; 105(9):1256-1262. PubMed ID: 30862619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab and adalimumab for uveitis.
    Martel JN; Esterberg E; Nagpal A; Acharya NR
    Ocul Immunol Inflamm; 2012 Feb; 20(1):18-26. PubMed ID: 22324897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF inhibition for ophthalmic indications: current status and outlook.
    Rifkin LM; Birnbaum AD; Goldstein DA
    BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Adalimumab and Infliximab for Noninfectious Uveitis.
    Tai F; Mehraban Far P; Pechlivanoglou P; Ramsay LC; Georgakopoulos JR; Sander B; Derzko-Dzulynsky LA; Felfeli T
    Ophthalmology; 2022 Mar; 129(3):357-359. PubMed ID: 34634363
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.
    Thorlund K; Druyts E; Mills EJ; Fedorak RN; Marshall JK
    J Crohns Colitis; 2014 Jul; 8(7):571-81. PubMed ID: 24491514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients With Noninfectious Uveitis.
    Bellur S; McHarg M; Kongwattananon W; Vitale S; Sen HN; Kodati S
    JAMA Ophthalmol; 2023 Feb; 141(2):150-156. PubMed ID: 36547953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
    Wendling D; Joshi A; Reilly P; Jalundhwala YJ; Mittal M; Bao Y
    Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.